Symetis, a Swiss biotechnology company, is planning an initial public offering in Zurich in the latest sign the nascent market for healthcare flotations in Europe is building steam.

The company, which develops heart valve replacement systems, has hired Credit Suisse to prepare it for a flotation, according to two people familiar with the matter.